[go: up one dir, main page]

WO1993010266A1 - Dispositif et procede de detection de composes qui s'intercalent avec des acides nucleiques - Google Patents

Dispositif et procede de detection de composes qui s'intercalent avec des acides nucleiques Download PDF

Info

Publication number
WO1993010266A1
WO1993010266A1 PCT/US1992/009916 US9209916W WO9310266A1 WO 1993010266 A1 WO1993010266 A1 WO 1993010266A1 US 9209916 W US9209916 W US 9209916W WO 9310266 A1 WO9310266 A1 WO 9310266A1
Authority
WO
WIPO (PCT)
Prior art keywords
waveguide
sample
nucleic acid
intercalating agent
light
Prior art date
Application number
PCT/US1992/009916
Other languages
English (en)
Inventor
Howard H. Weetall
Original Assignee
The United States Of America, Represented By The Secretary, United States Department Of Commerce
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by The United States Of America, Represented By The Secretary, United States Department Of Commerce filed Critical The United States Of America, Represented By The Secretary, United States Department Of Commerce
Publication of WO1993010266A1 publication Critical patent/WO1993010266A1/fr

Links

Classifications

    • G—PHYSICS
    • G01—MEASURING; TESTING
    • G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
    • G01N21/00—Investigating or analysing materials by the use of optical means, i.e. using sub-millimetre waves, infrared, visible or ultraviolet light
    • G01N21/62—Systems in which the material investigated is excited whereby it emits light or causes a change in wavelength of the incident light
    • G01N21/63—Systems in which the material investigated is excited whereby it emits light or causes a change in wavelength of the incident light optically excited
    • G01N21/64—Fluorescence; Phosphorescence
    • G01N21/645—Specially adapted constructive features of fluorimeters
    • G01N21/648—Specially adapted constructive features of fluorimeters using evanescent coupling or surface plasmon coupling for the excitation of fluorescence
    • G—PHYSICS
    • G01—MEASURING; TESTING
    • G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
    • G01N21/00—Investigating or analysing materials by the use of optical means, i.e. using sub-millimetre waves, infrared, visible or ultraviolet light
    • G01N21/62—Systems in which the material investigated is excited whereby it emits light or causes a change in wavelength of the incident light
    • G01N21/63—Systems in which the material investigated is excited whereby it emits light or causes a change in wavelength of the incident light optically excited
    • G01N21/64—Fluorescence; Phosphorescence
    • G01N21/6428—Measuring fluorescence of fluorescent products of reactions or of fluorochrome labelled reactive substances, e.g. measuring quenching effects, using measuring "optrodes"

Definitions

  • This invention relates to a device and method for detection and quantitation of compounds which interact with nucleic acids.
  • the application of evanescent wave technology using a fluorescent intercalating agent as the label offers a built in detection system.
  • the competitive inhibition of an intercalating fluorescent compound by any unknown nucleic acid interactive compound is detectable in real-time by the application of evanescent wave technology utilizing either planar or optical fiber architectures.
  • intercalation literally refers to the act of inserting into the calendar some extra time interval. In chemistry it describes the reversible insertion of a guest species into the lamellar host structure with maintenance of the structural features of the host. The term can also be applied to the biochemical phenomenon of complexation of a planar molecule within spirals of nucleic acids.
  • An essential feature of the intercalation reaction is that the guest and the host experience some degree of perturbation of their geometric, chemical, electronic or optical properties.
  • the bonding mechanism between guest and host molecules varies broadly from van der Waals forces to metallic and ionic bonding.
  • the guest species can often be exchanged for others.
  • a non-fluorescent guest can be exchanged for a fluorescent guest and vice-versa.
  • Polvintervalators echinomycin, quinomycin, triostin, BBM928A, tandem, diacridines, ethidium dimer, and ellipticene dimers, heterodimers and trimers
  • U.S. Patent No. 4,563,417 to Albarella et al. describes a nucleic acid hybridization assay method for detecting specific polynucleotide sequences.
  • a particular polynucleotide sequence is detected in a test medium containing a single stranded nucleic acid by forming a hybridization product comprising hybridized probe and a nucleic acid intercalator compound bound to double stranded nucleic acid.
  • the invention enables the detection of formed hybrids by inducing an immunogenic modification of double stranded nucleic acid in the region of hybridization.
  • Acridine orange is used as the intercal ⁇ ator compound.
  • Determining the binding of antibody to intercalation complexes can be accomplished in a variety of ways and preferably involves the use of antibody labeled with a detectable chemical group such as an enzymatically active group, a fluorescer, a luminescer, a specifically bindable ligand, or a radioisotope.
  • a detectable chemical group such as an enzymatically active group, a fluorescer, a luminescer, a specifically bindable ligand, or a radioisotope.
  • Albarella et al. use autoradiography or gamma counting as the method of detection.
  • U.S. Patent No. 5,001,051 to Miller et al. describes a method and apparatus for the n vivo and in vitro detection and measurement of the concentration of nucleic acids which is based on the inherent reaction or perturbation of anti-cancer drugs with DNA.
  • the method is based on the interaction of fluorescent or chromophoric dyes, particularly intercalating dyes, or other suitable labels which show a dramatic increase in a detectable signal.
  • the device used is a fiber optic sensor, one end of which carries a suitable support or substrate member, which is capable of binding and retaining the sensing reagents, and the other end of which is attached or connected to any suitable detection, recording and analyzing devices.
  • Sensing reagents include compounds which include fluorescent dyes, which may include intercalating dyes. Reactive groups such as a diazo- group facilitate the attachment or covalent bonding of fluorescent dye (ethidium derivative) or DNA to the surface of the glass bead. A change in the fluorescence of the ethidium dimer occurs when the probe is exposed to solutions of various therapeutic drugs. Miller et al. use fiber optic spectrometry as the method of detection. U.S. Patent No. 4,925,785 to Wang et al. describes a method for carrying out a nucleic acid hybrid ⁇ ization test to detect a target nucleic acid sequence (DNA or RNA) .
  • the advantages of the method include amplifica ⁇ tion of detectable signal, ability to employ large numbers of fluorescent labels while avoiding self quenching, simple detection of hybridization without the use of labels, etc.
  • the method of detection of a target nucleic acid of Wang et al. involves detecting changes in turbidity and gelation of the target nucleic acid.
  • U.S. Patent No. 4,407,942 to Birn mecanic describes a fluorescent method for the detection of damage to DNA caused by low doses of radiation. In this method, a selected fluorescent dye is used both to detect double stranded DNA and to monitor its rate of unwinding in alkaline media without the requirement for physical separation of single stranded from double stranded DNA. A kit adapted for carrying out the test method is also described.
  • Fluorescence is measured with a spectrofluoro- meter.
  • a labelled antigen probe competes with an unknown antigen for a limited number of antigen binding sites on an antibody.
  • U.S. Patent No. 4,582,809 to Block et al. discloses an apparatus including an optical fiber for fluorescence immunoassays.
  • the apparatus of Block et al. includes a radiation source, an optical fiber, means for attaching an immunochemical complex, such as an antibody, to an optical fiber, and a means for detecting radiation.
  • U.S. Patent No. 4,716,121 to Block et al. discloses a method for performing immunoassays using a fluorimeter and total internal reflection technology.
  • the disclosure of Block et al. does not allow for the sensitivity of detec ⁇ tion of compounds such as polynuclear aromatic compounds.
  • immunoassay sensitivity is limited by the binding constant of the antibody and does not allow for the sensitivity of detection achieved with ' the present invention which is about 100 times greater than immuno ⁇ assay sensitivity.
  • Another object of the present invention is to provide a method for the detection and quantitation of compounds found in aqueous environments. Another object of the invention is to provide a method for the detection of polynuclear aromatic compounds in a sample.
  • the present invention relates to a device and method for the detection and quantitation of compounds which interact with nucleic acids, such as DNA, using evanescent wave technology.
  • a nucleic acid, including double stranded DNA or RNA, attached to an evanescent waveguide is used to detect a known or unknown sample which intercalates with the nucleic acid by competitive inhibition of a fluorescent label at the solid surface of a waveguide.
  • the evanescent wave technology offers improved sensitivity, speed and simplicity, while the use of a fluorescent intercalating agent as the label offers a built in detection system.
  • This technique which utilizes the phenomenon of nucleic intercalation, has the advantage of being a highly sensitive assay for polynuclear aromatic hydrocarbons (PAH's), the assay architecture of which is similar to the architecture of the fluorescent label of the present invention.
  • PAH's polynuclear aromatic hydrocarbons
  • Figure 1 shows a preferred embodiment for a device for detection and quantitation of compounds which intercalate with DNA.
  • (1) represents a fiber optic waveguide with a nucleic acid bound thereto; (2) repre- sents a sample chamber; (3) represents a light source; (4) represents a focusing means; (5) represents a mirror; (6) represents a photodetector; (7) represents a sample entry port; (9) represents a sample exit port; ( ) represents an example of light refraction through the waveguide.
  • Figure 2 is a schematic diagram of how a sample competes with an intercalating agent for nucleic acid binding sites.
  • (1) represents a waveguide with a nucleic acid (2) bound thereto; (0) represents an intercalating agent;
  • ( ⁇ ) represents a sample competing for nucleic acid binding sites.
  • This invention provides a rapid, simple, and sensitive method for the detection and quantitation of several varieties compounds.
  • the present method may be used to detect samples of known or unknown compounds which intercalate with nucleic acids.
  • Such compounds which are known to interca ⁇ late with nucleic acids include but are not limited to acridine dyes, phenanthrides, phenazines, phenothiozines, quinolines, aflatoxin, polycyclic hydrocarbons, oxirane derivatives, actinomyces, anthracyclinones, thiaxanthe- nones, anthramycin, mitomycin, platinum complexes, polyintervalators, norphilin A, fluorenes, fluorenones, furocoumarins, benzodipyrones, and Monostral fast blue.
  • Examples of acridine dyes include proflavine, acridine orange, quinacrine, and acriflavine.
  • Examples of phenanthrides include ethidium, coralyne, ellipticine, ellipticine cation, and derivatives thereof.
  • An example of phenothiazine is chlorpromazine.
  • Examples of polycy-grass hydrocarbons include 3,4-benzopyrene and benzopyrene.
  • Examples of oxirane derivatives include diol epoxide, benzanthracene-5,6 oxide, and 1-pyrenyloxirane.
  • An example of actinomyces is actinycin D.
  • anthracyclinone examples include beta-rhodomycin A and duanomycin.
  • An example of a thiaxanthenone is miracil D.
  • polyintervalators include echinomycin, quinomycin, trios- tin, BBM928A, tandem (a tradename for 2-(3,5-dichloro- phenyl) -2-(2,22-trichloroethyl)oxirane) , diacridine dimers, ethidium dimers, ellipticene dimers, and hetero- dimers and trimers of ellipticene.
  • Fluorenes and fluoren ⁇ ones include fluorenodiamines.
  • Furocoumarins include angelicin, 4,5-dimethylangelicin, psoralen, 8-methoxypso- ralen, 5-aminomethyl-8-methoxypsoralen, 4,5,8-tri- methylpsoralen, xanthotoxin and khellin.
  • Fluorescent compounds in the above list may be used as the fluorescent intercalating agent or label to achieve the objects of the invention.
  • Preferred fluorescent intercalating agents include ethidium bromide and proflavone.
  • this interface is formed by a high refractive index quartz core and a thin layer or cladding of a lower index glass surrounding the core.
  • TIR can occur in a device of any shape, as long as the above optical criteria are met.
  • Other TIR elements may include flat plates and prisms.
  • the internally reflected light beam is conducted down the waveguide and emerges at the distal end in a defined shape of light (e.g., a cone for a cylindrical fiber) determined by the critical angle of the system. Light emerging from the distal end may be used to probe and monitor chemical reactions of compounds placed in front of it.
  • the transduced signal may include fluores ⁇ cence, absorption, or light scattering events.
  • the optical waveguide is a passive element merely delivering and receiving light in a highly effi- cient fashion.
  • a number of optical immuno-sensors have been assembled in this configuration and comprise the group known as distal tip sensors.
  • an electromagnetic field called the evanescent wave penetrates perpendicularly to the fiber axis a small distance (typically less than one wavelength) into the lower index medium. This field decays in amplitude exponentially with distance from the interface of the two optically different media.
  • the depth of penetration is a measure of the distance that defines where the amplitude of the evanescent wave has decayed 1/e of its magnitude at the interface - this is approximately 36% of the initial intensity.
  • the equation determining the depth of penetration involves the wavelength, the angle of incident light and the refractive index ratios of the two optically different media. When water or serum replaces the glass cladding and acts as the low index optical media, at an incident wavelength of 500 nm., the depth of penetration is about 100nm.
  • Sensitivity of detection is limited by the uniformity of the waveguide, minimization of light scatter and the amount of fluorescent light due to unbound fluoro- phors that makes its way into low angle emission.
  • Fiber optic sensors offer the greatest sensi ⁇ tivity for sample detection. Fiber optic sensors avoid spreading and loss of light in the transverse direction. Cylindrical symmetry of the fiber optic waveguide allows the entire surface area to be used for sensing and collec ⁇ tion of light. A large number of internal reflections in the fiber optic waveguide allows signal enhancement as every intercession of incident light with the surface generates a signal-creating evanescent wave, and fluores ⁇ cence that tunnels back into the fiber is concentrated in a bright spot on a small detector face, resulting in less electrical noise in the signal amplification process.
  • the method for the detection and quantitation of compounds which intercalate with a nucleic acid includes placing a fluorescent intercalating agent and a sample in close proximity to a waveguide coated with a nucleic acid.
  • the sample, nucleic acid and fluorescent intercalating agent are allowed to react, such that the sample competes with the fluorescent intercalating agent for nucleic acid binding sites.
  • An excitation light is passed through the waveguide with a nucleic acid bonded thereto to excite the fluorescent intercalating agent coming within the evanes ⁇ cent wave with the excitation light.
  • Radiated light is detected from the fluorescent intercalating agent at the initiating end with a photodetector. The radiated light is compared to a similar waveguide and fluorescent inter ⁇ calating agent value previously run in the absence of a sample.
  • the agents may be added separately or together or in any desired order.
  • the time for obtaining a signal may range from up to 30 seconds to 30 minutes or more. If the signal in the presence of an unknown sample is signif ⁇ icantly less than the control signal, then one can assume that an intercalator molecule was present in the unknown sample.
  • Calibration is carried out by measuring a series of known concentration standards in the same fluid matrix as the unknown.
  • the signal response parameter of the unknown sample is then quantified by extrapolation from a linearized standard curve.
  • Increased sensitivity may be obtained by "puls ⁇ ing" the sample with fresh buffer to remove unreacted fluorescent intercalating agent from the vicinity of the fiber.
  • the buffer should be of a pH and ion concentration which will not cause release of bound fluorescent mole ⁇ cules or sample from the nucleic acid and should allow for maximum fluorescence of the fluorescent molecule.
  • the sample fluid may be buffered in the range of pH 6-9, preferably pH 7-8.
  • Various buffers such as borate, tris, carbonate and the like may be employed.
  • an unknown aqueous sample is added to a nucleic acid containing fiber attached to the waveguide device, surrounded by a capil ⁇ lary like tube which holds the liquid.
  • the sample may be as small as 10 to 100 microliters.
  • the tube containing the sample may also contain dried fluorescent intercalat ⁇ ing agent, in micromolar amounts, which becomes dissolved in the sample.
  • the molar concentration of the fluorescent intercalating agent is preferably 10 ⁇ 3 to 10 ⁇ 6 .
  • the reagents are allowed to react until enough signal is observed to obtain a difference between a similar fiber and fluorescent intercalating agent value previously run the absence of any unknown.
  • the fluorescent intercalating agent includes compounds selected from the above listing of compounds which are known to intercalate with nucleic acids.
  • the fluorescent intercalating agent is selected so that it possesses a different emission spectra than the compound to be detected in the sample. A skilled artisan will be able to select the appropriate fluorescent intercalating agent.
  • the present invention in a preferred embodiment includes a method for the detection and quantitation of compounds found in aqueous environments.
  • the preferred sample size for detecting com ⁇ pounds present in aqueous environments is 10 to 100 microliters.
  • the preferred reaction time between the intercalating agent, nucleic acid and sample is 30 sec. to 30 min.
  • An intercalation assay utilizing a solution format and fluorescence polarization methodology showed an average sensitivity of 5-10 picomoles/ml in the assay. This represents a concentration of 10 ⁇ 15 moles of compound detected/ml of solution tested.
  • the results of the present invention show a 100-fold improvement over these data for DNA detection experiments, also using ethidium bromide as the fluorescent intercalating agent.
  • Most assays proposed today for the rapid detec ⁇ tion of organic compounds at low concentration involve use of monoclonal antibodies specific for the antigen (organic compound) of interest.
  • the use of antibody assay tech ⁇ nology for the detection and quantitation of pesticides and polynuclear aromatic hydrocarbons (PAH's) has several important drawbacks which should be considered.
  • antibodies are by their nature highly specific. This is useful if one wants to detect a specific compound, but not useful if one wants to detect a class of compounds.
  • airborne carcinogens such as pesticides
  • the known methods require the collection and analysis of pesticides generally over 24 hour air sampling times plus analysis time.
  • the current method recommended by the EPA requires 24 hour sample collections utilizing air sampling devices which sample approximately 5-6m 3 of air.
  • Current analysis utilizes gas chromatograph/mass spectroscopy (GC/MS) or gas chromatograph/electron capture detection (GC/ECD) for quantification.
  • GC/MS gas chromatograph/mass spectroscopy
  • GC/ECD gas chromatograph/electron capture detection
  • Current methods of analysis of semi-volatile polynuclear aromatic hydrocarbon com ⁇ pounds (PAH's) are even more difficult, requiring filter collection of 15-20 L/min of air for 12-24 hours (150 m 3 ) to provide sufficient PAH's for detection using GC/MS (electron or chemical ionization) .
  • Minimal detectable levels of pesticides by known methods require from 1-100 ng/m 3 residues in air collected, while with PAH's the level is in the range of 0.1 ng/m 3 of collected air.
  • the total required amount of sample for detection of pesticides is somewhere between
  • the method of the invention may include placing an intercalating agent and a sample of air which has been dissolved in a liquid solu ⁇ tion adjacent to a waveguide coated with a nucleic acid.
  • the sample, nucleic acid and intercalating agent are allowed to react, such that the sample competes with the intercalating agent for nucleic acid binding site.
  • An excitation light is passed through the waveguide to excite the intercalating agent coming within an evanescent wave of the excitation light.
  • Radiated light from the interca ⁇ lating agent is detected at the initiating end of the waveguide, and the radiated light is compared to a similar waveguide and intercalating agent value previously run in the absence of a sample.
  • the present method allows detection and quanti- tation of toxin levels of 10 ⁇ 17 moles to 10 "15 moles with little difficulty. This being the case, the quantity of air required would be less than 1/1000th of the presently required 5-50 m 3 of air now collected. At the rate of 4-40 liters/min this means that collection times could be cut to approximately 2-20 minutes total time. Since the air collection time is so short, it should be possible to collect air directly into the assay solution, thus avoiding the filter collection and subsequent organic extraction procedures required for GC/MS analysis.
  • a sample of air may be collected which comprises between 4-40 liters/min of air, with a concentration of 0.1-500 ng/m 3 for analytes of molecular weights in the 100-500 Dalton range. The concentrations of interest would be approximately 0.01 to 1.0 nanomole/m 3 of collected air.
  • Immunoassay sensitivity is limited by the binding constant Of the antibody as described in the general mass action equation. Since antibody binding constants average in the 10 7 to 10 9 L/mole range, the sensitivity of these known assays is generally limited to the 10 ⁇ 8 to 10 ⁇ 10 moles/L range. For most compounds this represents the low ng/ml concentration range. In the case of PAH's and pesticides, this sensitivity range is sufficient for analysis of 24 hour collection, but not sufficient for short on the spot analysis where sensitivity in excess of 100 fold is required.
  • Antibodies are capable of detecting specific compounds at concentrations equivalent to concentrations detected by GC/MS methods.
  • the intercalation of a compound with nucleic acids as in the present method using an evanescent waveguide device allows for greater sensi- tivity of samples containing lower concentrations of compounds.
  • the present invention also includes a method for the detection of polynuclear aromatic compounds in a sample, includes placing an intercalating agent and a polynuclear aromatic compound sample in close proximity to a waveguide coated with a nucleic acid.
  • the sample, nucleic acid and intercalating agent are allowed to react, such that the sample competes with the intercalating agent for nucleic acid binding sites.
  • An excitation light is passed through said waveguide to excite the intercalating agent coming within an evanescent wave of said excitation light.
  • Radiated light from the intercalating agent is detected at the initiating end of the waveguide, and the radiated light is compared to a similar waveguide and intercalating agent value previously run in the absence of a sample.
  • a device for detection and quantitation of com ⁇ pounds which intercalate with nucleic acids of the present invention may include a chamber for a sample to be tested (2); a waveguide with a nucleic acid bonded thereto (1), wherein the waveguide is proximally located to the sample in the chamber.
  • a light source (3) at a first end of the waveguide is capable of shining monochromatic light at a wavelength of excitation of an intercalating agent bound to the nucleic acid, and of passing an excitation light through the waveguide via evanescence.
  • a photodetector (6) at the first end of the waveguide detects radiated light emitted from said intercalating agent excited by the light source.
  • the device may also include a focuser such as a lens or the like for focusing light from the light source through the waveguide.
  • the focuser may be separate from the wave ⁇ guide, as in a lens (4), or may be a portion of the waveguide.
  • the device may include a mirror (5) angularly disposed between the focuser and the photodetector.
  • the mirror may preferably be a dichroic mirror, and may act as a low pass interfer ⁇ ence filter with a cut off frequency chosen to be between the frequencies of maximum absorption and maximum fluores- cence emission of the fluorescent intercalating agent of interest.
  • the waveguide may preferably be composed of glass, silica, quartz, ceramic, plastic, polyolefin, nylon or any polymer having a suitable refractive index.
  • the waveguide may preferably be an optical fiber, slide or planar plate.
  • a fiber optic waveguide has a diameter in the range of 200 microns to 1 mm and a length of from about 25 mm to 50 mm.
  • the light source may preferably be a tungsten halogen lamp, a mercury lamp, a flash lamp, or a laser.
  • the light source is chosen to maximize the fluorescence of the fluorescent intercalating agent.
  • Silicon diodes may preferably be used as the photodetector.
  • a ratio amplifier may be connected to the output of the photodetector and further connected to an input for display.
  • Display may be achieved by any of a number of devices which provides a visual signal representative of an electrical input and may be, for example, a digital display, a strip chart recorder or a meter.
  • a waveguide preferably made of glass, silica, quartz, polyolefin, nylon or plastic may be coated with a nucleic acid via silanization, covalent coupling or direct absorption.
  • the waveguide is chosen to have a refractive index greater than that of the sample.
  • An aqueous sample typically has an index of refraction near 1.33 and a serum sample has an index of refraction near 1.35. If a plastic waveguide is used, the plastic material must be of low florescence, and optically clear.
  • a method for preparing the surface of the waveguide, of attaching a silyl compound thereto, and of covalently bonding a nucleic acid to the glass via silyl coupling is described in Weetall, U.S. Patent No. 3,652,761, which is incorporated herein by reference. Other known techniques are also available for attaching a nucleic acid to a solid support.
  • the nucleic acid may take the form of double stranded DNA, double stranded RNA, a DNA/RNA complex or hybrid molecule, or natural or synthetic analogue, frag ⁇ ment or derivative thereof.
  • the amount of nucleic acid required to coat the waveguide is about 1 microgram or less.
  • the nucleic acid should be in a form which is easily obtainable. Any nucleic acid of known sequence is appropriate. The use of a linearized plasmid is pre ⁇ ferred; however oligonucleotides of known sequence may also be used. Suitable nucleic acids may be obtained from Sigma Chemical Co., St. Louis, Missouri. For example, double stranded DNA can be laid down in such a fashion that the majority of the molecules lay along the surface of the waveguide.
  • the waveguide is washed with buffer to remove excess DNA and dried until needed.
  • the wash buffer should be of high ionic strength (0.5M-2.0M) in order to remove adsorbed DNA.
  • the wash buffer should be of low ionic strength, preferably 0.01-0:1M.
  • Buffers prefer ⁇ ably include phosphate, carbonate and borate, for example.
  • any fluorescent intercalating agent coming within the evanescent wave is excited and radiates light back through the fiber and this light is detected at the initiating end of the fiber by a photode ⁇ tector. Since the photodetector and light source are constantly in operation, the binding of the fluorescent intercalating agent can be monitored as it occurs.
  • the addition of a known or unknown sample to this system which is capable of intercalating with the nucleic acid will cause competition for the available binding sites. Therefore the more sample present, the less fluorescent intercalating agent will bind. The less known or unknown sample present, the more the fluorescent intercalating agent will bind to the waveguide coated with a nucleic acid.
  • EXAMPLE 1 1 micromole of ethidium bromide in a 10 micro- liter sample of rainwater is placed in contact with a silica fiber optic waveguide of 1 mm in diameter and 50 mm in length (obtained from Corning, Incorporated, Corning, N.Y. or ORD, Corp. Nashua, NH) .
  • the waveguide is coated with double stranded DNA (obtained from Sigma Chemical Co. ) .
  • the sample, double stranded DNA and ethidium bromide are reacted for 15 minutes.
  • Light from a tungsten halogen lamp which emits light of a wavelength of 500 nm is passed through the fiber optic waveguide.
  • a lens is employed to image the light source on the end face of the fiber optic waveguide, and to collect all radiation exiting the end face of the fiber optic waveguide and direct the radiated light at the photo ⁇ detector.
  • a dichroic mirror which acts as a light filter.
  • a silicon diode photodetector detects radiated light due to the binding of ethidium bromide.
  • the value of the radiated light is compared to a standard value to reveal the amount of the sample.
  • the sample is found to contain 2.0 ng/ l of sample when comparing the radiated light to a similar waveguide and ethidium bromide value previously run in the absence of a sample.
  • EXAMPLE 2 1.5 micromole of acriflavine (obtained from Aldrich Chem. Co., Milwaukee, Wise.) in a 15 microuter sample of groundwater is placed adjacent to a silica fiber optic waveguide of 1 mm in diameter and 50 mm in length (obtained from ORD Corp., Nashua, NH) . The waveguide is coated with double stranded DNA.
  • the sample, double stranded DNA and acriflavine are reacted for 5 minutes.
  • Light from a tungsten halogen lamp which emits light of a wavelength of 500 nm is passed through the fiber optic waveguide.
  • a lens is employed to image the light source on the end face of the fiber optic waveguide, and to collect all radiation exiting the end face of the fiber optic waveguide and direct the radiated light at the photo detector.
  • a dichroic mirror which acts as a light filter.
  • a silicon diode photodetector detects radiated light due to the binding of acriflavine. The value of the radiated light is compared to a standard value to reveal the amount of the sample. The sample is found to contain 15 ng/ml of sample comparing the radiated light to a similar waveguide and acriflavine value previously run in the absence of a sample.
  • the waveguide is coated with double stranded RNA.
  • the sample, double stranded RNA and proflavone are reacted for 8 minutes.
  • Light from a mercury lamp which emits light of a wavelength of 500 nm is passed through the fiber optic waveguide.
  • a lens is employed to image the light source on the end face of the fiber optic waveguide, and to collect all radiation exiting the end face of the fiber optic waveguide and direct the radiated light at the photo detector.
  • a dichroic mirror which acts as a light filter.
  • a silicon diode photodetector detects radiated light due to the binding of proflavone.
  • the value of the radiated light is compared to a standard value to reveal the amount of sample.
  • the sample is found to contain 10 ng/ml of sample when comparing the radiated light to a similar waveguide and proflavone value previously run in the absence of a sample.
  • a 10 liter/min sample of air is collected for a period of 5 minutes through a bubble trap containing 10 ml of 0.01 M phosphate buffer and placed into a sealed chamber.
  • a sample containing 100 ⁇ l of this solution is placed is placed adjacent to a quartz fiber optic wave ⁇ guide of 1 mm in diameter and 50 mm in length (obtained from ORD Corp.).
  • the waveguide is coated with double stranded RNA (obtained from Sigma Chemical Co) .
  • 2 micromoles of 10" 5 M acridine orange obtained from Aldrich Chemical Co.
  • the dissolved air sample, acridine orange and RNA are reacted for 30 minutes.
  • Light from a tungsten halogen lamp which emits light of a wavelength of 500 nm is passed through the fiber optic waveguide.
  • a silicon diode photodetector detects radiated light due to the binding of acridine orange.
  • the value of the radiated light is compared to a standard value to reveal the amount of the sample.
  • the sample is found to contain 0.1 ng/ml of added sample when comparing the radiated light to a similar waveguide and acridine orange value previously run in the absence of a sample.
  • a 20 liter/min sample of air is collected through a 10 ml bubble trap as previously described for a period of 10 minutes and placed into a sealed chamber.
  • the air is dissolved in 40 microliters of distilled water for 10 minutes.
  • a 100 ⁇ l sample in the buffer is placed in contact with a glass planar waveguide (Glass Microscope cover slip) of 1 mm in thickness and 50 mm in length
  • the waveguide is coated with a DNA/RNA hybrid.
  • ethidium bromide 1 micromole of ethidium bromide as the interca- lating agent is added to the waveguide and sample.
  • the dissolved air sample, ethidium bromide and RNA are reacted for 5 minutes.
  • a silicon diode photodetector detects radiated light due to the binding of ethidium bromide.
  • the value of the radiated light is compared to a standard value to reveal the amount of the unknown sample.
  • the sample is found to contain 0.01 ng/ml of unknown sample when compar ⁇ ing the radiated light to a similar waveguide and ethidium bromide value previously run in the absence of a sample.

Landscapes

  • Health & Medical Sciences (AREA)
  • Immunology (AREA)
  • Chemical & Material Sciences (AREA)
  • Physics & Mathematics (AREA)
  • Biochemistry (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Analytical Chemistry (AREA)
  • General Health & Medical Sciences (AREA)
  • General Physics & Mathematics (AREA)
  • Pathology (AREA)
  • Optics & Photonics (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Investigating, Analyzing Materials By Fluorescence Or Luminescence (AREA)
  • Measuring Or Testing Involving Enzymes Or Micro-Organisms (AREA)

Abstract

Dans un dispositif et procédé de détection et de quantification de composés qui ont une interaction avec l'ADN, l'application d'une technologie à onde évanescente utilisant un agent d'intercalation fluorescent en tant qu'étiquette permet d'obtenir un système incorporé de détection. L'inhibition compétitive d'un composé fluorescent d'intercalation par un quelconque composé inconnu interactif avec l'ADN est détectable en temps réel par application d'une technologie à onde évanescente utilisant des architectures de fibre optique ou plane.
PCT/US1992/009916 1991-11-22 1992-11-20 Dispositif et procede de detection de composes qui s'intercalent avec des acides nucleiques WO1993010266A1 (fr)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
US79639191A 1991-11-22 1991-11-22
US07/796,391 1991-11-22

Publications (1)

Publication Number Publication Date
WO1993010266A1 true WO1993010266A1 (fr) 1993-05-27

Family

ID=25168091

Family Applications (1)

Application Number Title Priority Date Filing Date
PCT/US1992/009916 WO1993010266A1 (fr) 1991-11-22 1992-11-20 Dispositif et procede de detection de composes qui s'intercalent avec des acides nucleiques

Country Status (2)

Country Link
AU (1) AU3140293A (fr)
WO (1) WO1993010266A1 (fr)

Cited By (5)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
EP0562765A3 (fr) * 1992-03-25 1994-04-06 Lilly Co Eli
WO1995026416A1 (fr) * 1994-03-25 1995-10-05 Research Corporation Technologies, Inc. Procede de diagnostic par biocapteurs d'acide nucleique
WO2000020633A1 (fr) * 1998-10-08 2000-04-13 Hybaid Limited Detection d'un polymorphisme d'acide nucleique
US6503711B1 (en) 1997-06-18 2003-01-07 Ulrich J. Krull Nucleic acid biosensor diagnostics
WO2019151864A1 (fr) * 2018-02-05 2019-08-08 Lumicks Technologies B.V. Procédés et dispositifs pour déterminer une structure invitée sur une structure hôte

Citations (5)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US4257774A (en) * 1979-07-16 1981-03-24 Meloy Laboratories, Inc. Intercalation inhibition assay for compounds that interact with DNA or RNA
US4563417A (en) * 1984-08-31 1986-01-07 Miles Laboratories, Inc. Nucleic acid hybridization assay employing antibodies to intercalation complexes
EP0245206A1 (fr) * 1986-05-05 1987-11-11 IntraCel Corporation Méthode analytique de détection et de mesure d'un acide nucléique spécifiquement séquencé
US4777129A (en) * 1983-12-12 1988-10-11 Molecular Diagnostics, Inc. Nucleic acid probe detectable by specific nucleic acid binding protein
US5001051A (en) * 1986-12-12 1991-03-19 Regents Of The University Of California Dose critical in-vivo detection of anti-cancer drug levels in blood

Patent Citations (5)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US4257774A (en) * 1979-07-16 1981-03-24 Meloy Laboratories, Inc. Intercalation inhibition assay for compounds that interact with DNA or RNA
US4777129A (en) * 1983-12-12 1988-10-11 Molecular Diagnostics, Inc. Nucleic acid probe detectable by specific nucleic acid binding protein
US4563417A (en) * 1984-08-31 1986-01-07 Miles Laboratories, Inc. Nucleic acid hybridization assay employing antibodies to intercalation complexes
EP0245206A1 (fr) * 1986-05-05 1987-11-11 IntraCel Corporation Méthode analytique de détection et de mesure d'un acide nucléique spécifiquement séquencé
US5001051A (en) * 1986-12-12 1991-03-19 Regents Of The University Of California Dose critical in-vivo detection of anti-cancer drug levels in blood

Non-Patent Citations (1)

* Cited by examiner, † Cited by third party
Title
TIBTECH, Vol. 8, issued June 1990, BLUESTEIN et al., "Fiber Optic Evanescent Wave Immunosensors for Medical Diagnostics", page 1-8. *

Cited By (8)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
EP0562765A3 (fr) * 1992-03-25 1994-04-06 Lilly Co Eli
WO1995026416A1 (fr) * 1994-03-25 1995-10-05 Research Corporation Technologies, Inc. Procede de diagnostic par biocapteurs d'acide nucleique
US6503711B1 (en) 1997-06-18 2003-01-07 Ulrich J. Krull Nucleic acid biosensor diagnostics
WO2000020633A1 (fr) * 1998-10-08 2000-04-13 Hybaid Limited Detection d'un polymorphisme d'acide nucleique
WO2019151864A1 (fr) * 2018-02-05 2019-08-08 Lumicks Technologies B.V. Procédés et dispositifs pour déterminer une structure invitée sur une structure hôte
NL2020377B1 (en) * 2018-02-05 2019-08-14 Lumicks Tech B V Methods and devices for determining a guest structure on a host structure
US11187656B2 (en) 2018-02-05 2021-11-30 Lumicks Dsm Holding B.V. Methods and devices for determining a guest structure on a host structure
US11885809B2 (en) 2018-02-05 2024-01-30 Lumicks Dsm Holding B.V. Methods and devices for determining a guest structure on a host structure

Also Published As

Publication number Publication date
AU3140293A (en) 1993-06-15

Similar Documents

Publication Publication Date Title
US4447546A (en) Fluorescent immunoassay employing optical fiber in capillary tube
EP0128723B1 (fr) Appareil et méthodes d'essai
US6534011B1 (en) Device for detecting biochemical or chemical substances by fluorescence excitation
US5266498A (en) Ligand binding assay for an analyte using surface-enhanced scattering (SERS) signal
US5959292A (en) Process for detecting evanescently excited luminescence
US4582809A (en) Apparatus including optical fiber for fluorescence immunoassay
AU591070B2 (en) Assay technique and equipment
US6008057A (en) Immunoassay system
US20140170674A1 (en) Membraine-Based Assay Devices Utilizing Time-Resolved Up-Converting Luminescence
JP2003512625A (ja) 磁気クロマトグラフィ測定法を行うためのシステムおよび方法
JP2000506277A (ja) 被検体を測定する方法および検査ストリップ
EP0382832B1 (fr) Methode d'analyse d'un ligand dans un echantillon
CN101548186A (zh) 检测样品中的目标分子
WO2010086942A1 (fr) Analyseur automatique
EP0488152A2 (fr) Procédé pour immuno-essai et appareil pour sa mise en oeuvre
US20040047770A1 (en) Cuvette for a reader device for assaying substances using the evanescence field method
WO1993010266A1 (fr) Dispositif et procede de detection de composes qui s'intercalent avec des acides nucleiques
JP4480130B2 (ja) 光学分析装置
JP2011209108A (ja) 測定用基板、並びに、これを用いた生化学的結合形成および生化学的結合量の測定方法
JPS61502418A (ja) 光学分析方法及び装置
RU2197732C1 (ru) Способ обнаружения и идентификации клеток микроорганизмов и вирусов
US20140014856A1 (en) Biosensor
WO2010041736A1 (fr) Procédé de dosage utilisant un plasmon de surface
JP2005077396A (ja) 分析用光導波路
CN219038823U (zh) 一种基于磁性纳米颗粒的微流控式即时免疫检测装置

Legal Events

Date Code Title Description
AK Designated states

Kind code of ref document: A1

Designated state(s): AU CA JP

AL Designated countries for regional patents

Kind code of ref document: A1

Designated state(s): AT BE CH DE DK ES FR GB GR IE IT LU MC NL SE

DFPE Request for preliminary examination filed prior to expiration of 19th month from priority date (pct application filed before 20040101)
122 Ep: pct application non-entry in european phase
NENP Non-entry into the national phase

Ref country code: CA